MIST Milestone Pharmaceuticals
- 1.870
- +0.020+1.08%
Milestone Pharmaceuticals News
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $9
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $5
Milestone Pharmaceuticals (MIST) Gets a Buy From Piper Sandler
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $9
Strategic Positioning and Financial Outlook: Ritu Baral's Buy Rating on Milestone Pharmaceuticals Amidst Etripamil's Promising Market Launch
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $9
Milestone Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $9
TD Cowen Sticks to Its Buy Rating for Milestone Pharmaceuticals (MIST)
Rodman & Renshaw Initiates Milestone Pharmaceuticals(MIST.US) With Buy Rating, Announces Target Price $9
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Milestone Pharmaceuticals: A Buy Rating on CARDAMYST's Market Potential and FDA Progress
Rodman & Renshaw Initiates Coverage On Milestone Pharmaceuticals With Buy Rating, Announces Price Target of $9
Milestone Pharmaceuticals Analyst Ratings
Piper Sandler Sticks to Their Buy Rating for Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Milestone Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Analysis
Price Target
No Data
No Data